Connection
Robert Griffin to Biological Availability
This is a "connection" page, showing publications Robert Griffin has written about Biological Availability.
|
|
Connection Strength |
|
|
|
|
|
0.232 |
|
|
|
-
Hanley MJ, Zhang S, Griffin R, Zhu SX, Fram RJ, Lin J, Venkatakrishnan K, Gupta N. A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Invest New Drugs. 2024 Aug; 42(4):343-352.
Score: 0.232